Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir versus darunavir/ritonavir in treatment-naive adults with HIV-1
2011-003629-86Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Human immunodeficiency virus infection type 1 comparing Dolutegravir arm with Darunavir/ritonavir arm (2 arms). Primary endpoint: Proportion of subjects with HIV-1 RNA below 50 copies/mL through Week 48. Started Nov 2011; status: completed.
02
Drugs
dolutegravirdarunavirritonavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2011-003629-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003629-86.